Atlas Trials

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Clinical trial NCT03212404 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03212404
Sponsor
Checkpoint Therapeutics, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Lung NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Small CellMalignant Mesothelioma, AdvancedHead and Neck CancerMelanomaMerkel Cell CarcinomaRenal Cell CarcinomaUrothelial CarcinomaClassical Hodgkin LymphomaCutaneous Squamous Cell CarcinomaNon Hodgkin Lymphoma
Start date
2017-09-20
Primary completion
2021-11-18
Enrollment
272

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.